MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1200/jco.22.01076

Медицинская библиотека · Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022

Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.

Schultz Liora M, Eaton Anne, Baggott Christina, Rossoff Jenna, Prabhu Snehit, Keating Amy K, Krupski Christa, Pacenta Holly, Philips Christine L, Talano Julie-An, Moskop Amy, Baumeister Susanne H C, Myers Gary Douglas, Karras Nicole A, Brown Patrick A, Qayed Muna, Hermiston Michelle, Satwani Prakash, Wilcox Rachel, Rabik Cara A, Fabrizio Vanessa A, Chinnabhandar Vasant, Kunicki Michael, Mavroukakis Sharon, Egeler Emily, Li Yimei, Mackall Crystal L, Curran Kevin J, Verneris Michael R, Laetsch Theodore W, Stefanski Heather

СтатьяПоддержка NIH: внешняя программаПоддержка исследования: вне правительства СШАПеревод в очереди

Аннотация

PURPOSE: Nonresponse and relapse after CD19-chimeric antigen receptor (CAR) T-cell therapy continue to challenge survival outcomes. Phase II landmark data from the ELIANA trial demonstrated nonresponse and relapse rates of 14.5% and 28%, respectively, whereas use in the real-world setting showed nonresponse and relapse rates of 15% and 37%. Outcome analyses describing fate after post-CAR nonresponse and relapse remain limited. Here, we aim to establish survival outcomes after nonresponse and both CD19+ and CD19- relapses and explore treatment variables associated with inferior survival.

METHODS

We conducted a retrospective multi-institutional study of 80 children and young adults with B-cell acute lymphoblastic leukemia experiencing nonresponse (n = 23) or relapse (n = 57) after tisagenlecleucel. We analyze associations between baseline characteristics and these outcomes and establish survival rates and salvage approaches.

RESULTS

The overall survival (OS) at 12 months was 19% across nonresponders (n = 23; 95% CI, 7 to 50). Ninety-five percent of patients with nonresponse had high preinfusion disease burden. Among 156 morphologic responders, the cumulative incidence of relapse was 37% (95% CI, 30 to 47) at 12 months (CD19+; 21% [15 to 29], CD19-; 16% [11 to 24], median follow-up; 380 days). Across 57 patients experiencing relapse, the OS was 52% (95% CI, 38 to 71) at 12 months after time of relapse. Notably, CD19- relapse was associated with significantly decreased OS as compared with patients who relapsed with conserved CD19 expression (CD19- 12-month OS; 30% [14 to 66], CD19+ 12-month OS; 68% [49 to 92], P = .0068). Inotuzumab, CAR reinfusion, and chemotherapy were used as postrelapse salvage therapy with greatest frequency, yet high variability in treatment sequencing and responses limits efficacy analysis across salvage approaches.

CONCLUSION

We describe poor survival across patients experiencing nonresponse to tisagenlecleucel. In the post-tisagenlecleucel relapse setting, patients can be salvaged; however, CD19- relapse is distinctly associated with decreased survival outcomes.

Для цитирования: Schultz Liora M, Eaton Anne, Baggott Christina, Rossoff Jenna, Prabhu Snehit, Keating Amy K, Krupski Christa, Pacenta Holly, Philips Christine L, Talano Julie-An, Moskop Amy, Baumeister Susanne H C, Myers Gary Douglas, Karras Nicole A, Brown Patrick A, Qayed Muna, Hermiston Michelle, Satwani Prakash, Wilcox Rachel, Rabik Cara A, Fabrizio Vanessa A, Chinnabhandar Vasant, Kunicki Michael, Mavroukakis Sharon, Egeler Emily, Li Yimei, Mackall Crystal L, Curran Kevin J, Verneris Michael R, Laetsch Theodore W, Stefanski Heather. Outcomes After Nonresponse and Relapse Post-Tisagenlecleucel in Children, Adolescents, and Young Adults With B-Cell Acute Lymphoblastic Leukemia.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2022. DOI: 10.1200/jco.22.01076.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.